Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Shell Asset Management Co. increased its stake in BioNTech SE by 15.3%, acquiring 5,398 shares to reach a total of 40,610 shares worth approximately $4.32 million.
• BioNTech reported a quarterly EPS of ($1.60), missing consensus estimates, but revenue surged by 102.6% year-over-year to $306.46 million.
• Analysts have a consensus rating of "Moderate Buy" on BioNTech, with an average price target of $134.46, while several firms have set targets ranging from $136 to $150.

Shell Asset Management Co. lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 15.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,610 shares of the company's stock after buying an additional 5,398 shares during the period. Shell Asset Management Co.'s holdings in BioNTech were worth $4,324,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise acquired a new position in BioNTech in the first quarter worth about $36,000. Banque Transatlantique SA acquired a new stake in BioNTech during the 1st quarter worth $80,000. Costello Asset Management INC acquired a new stake in BioNTech during the 1st quarter worth $91,000. Goodman Advisory Group LLC acquired a new stake in BioNTech during the 1st quarter worth $105,000. Finally, NewEdge Advisors LLC acquired a new stake in BioNTech during the 1st quarter worth $167,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $106.06 on Wednesday. The company has a market cap of $25.50 billion, a price-to-earnings ratio of -66.29 and a beta of 1.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm has a 50 day simple moving average of $104.72 and a 200 day simple moving average of $103.44. BioNTech SE Sponsored ADR has a one year low of $81.20 and a one year high of $129.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. During the same period in the previous year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. Research analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and set a $136.00 price target on shares of BioNTech in a research report on Monday, September 8th. Bank of America boosted their price objective on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley boosted their price objective on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of BioNTech in a research note on Saturday, September 27th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $134.46.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.